Glenmark is the first company in India to have received the regulator’s approval for 400 mg dosage form Increased strength of FabiFlu® yet another milestone...

Phase 3 Trial Demonstrates Statistically Significant Faster Time to Clinical Improvement with Favipiravir Treatment in Mild to Moderate COVID 19 Patients Compared to Control...

Also, due to better yield and scale, Glenmark passes the benefits to patients by reducing the price of oral antiviral FabiFlu® by 27 %...

Glenmark introduces 3-in-1 inhaler therapy for COPD, promising reduction in risk of severe attacks and improvement in lung function AIRZ-FF is India’s first Glycopyrronium +...

Glenmark pledges support for 10,000 meals for daily wage earners and other needy groups and extends aid  to  women and children across 70 villages...